BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering
BioSig Technologies (NASDAQ: BSGM), recently merged with Streamex Exchange Corporation, has completed a $15 million public offering of common stock. The company sold 3,852,149 shares at $3.90 per share, with no pre-funded warrants included in the structure.
The offering, managed jointly by Clear Street and Needham & Company, was conducted under an effective S-3 shelf registration. The net proceeds will be primarily used to purchase gold bullion in accordance with the company's investment policy, along with general corporate purposes and working capital needs.
BioSig Technologies (NASDAQ: BSGM), recentemente fusa con Streamex Exchange Corporation, ha completato un collocamento pubblico da 15 milioni di dollari di azioni ordinarie. La societ脿 ha venduto 3.852.149 azioni a 3,90 $ per azione, senza includere warrant prefinanziati nella struttura dell'operazione.
L'offerta, gestita congiuntamente da Clear Street e Needham & Company, 猫 stata effettuata ai sensi di un'efficace registrazione S-3. I proventi netti saranno utilizzati principalmente per l'acquisto di lingotti d'oro in conformit脿 con la politica di investimento della societ脿, oltre che per scopi aziendali generali e capitale circolante.
BioSig Technologies (NASDAQ: BSGM), recientemente fusionada con Streamex Exchange Corporation, ha completado una oferta p煤blica de 15 millones de d贸lares de acciones ordinarias. La compa帽铆a vendi贸 3.852.149 acciones a 3,90 $ por acci贸n, sin incluir warrants prefinanciados en la estructura.
La oferta, gestionada conjuntamente por Clear Street y Needham & Company, se llev贸 a cabo bajo una inscripci贸n S-3 en vigor. Los ingresos netos se destinar谩n principalmente a la compra de lingotes de oro conforme a la pol铆tica de inversi贸n de la empresa, adem谩s de para fines corporativos generales y necesidades de capital de trabajo.
BioSig Technologies (NASDAQ: BSGM)電� 斓滉芳 Streamex Exchange Corporation瓿� 頃╇硲鞚� 毵堨箻瓿� 1,500毵� 雼煬 攴滊鞚� 瓿店皽 欤检嫕 氚滍枆鞚� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 欤茧嫻 3.90雼煬鞐� 3,852,149欤茧ゼ 韺愲Г頄堨溂氅�, 甑“鞐� 靷爠 鞛愱笀 歆�旮� 鞗岆煱韸鸽姅 韽暔霅橃 鞎婌晿鞀惦媹雼�.
鞚措矆 氚滍枆鞚� Clear Street鞕� Needham & Company臧� 瓿惦彊鞙茧 欤缄磤頄堨溂氅� 鞙犿毃頃� S-3 靹滊鞐� 霐半澕 歆勴枆霅橃棃鞀惦媹雼�. 靾滌垬鞚奠潃 須岇偓鞚� 韴瀽鞝曥眳鞐� 霐半澕 欤茧 旮堦创 甑Г鞐� 靷毄霅橂┌, 攴� 鞕� 鞚茧皹 旮办梾 氇╈爜瓿� 鞖挫爠 鞛愲掣鞙茧霃� 頇滌毄霅� 鞓堨爼鞛呺媹雼�.
BioSig Technologies (NASDAQ: BSGM), r茅cemment fusionn茅e avec Streamex Exchange Corporation, a r茅alis茅 une offre publique de 15 millions de dollars d'actions ordinaires. La soci茅t茅 a vendu 3 852 149 actions 脿 3,90 $ par action, sans inclure de bons de souscription pr茅financ茅s dans la structure.
L'offre, g茅r茅e conjointement par Clear Street et Needham & Company, a 茅t茅 effectu茅e en vertu d'un enregistrement S-3 effectif. Le produit net servira principalement 脿 l'achat de lingots d'or conform茅ment 脿 la politique d'investissement de la soci茅t茅, ainsi qu'脿 des fins g茅n茅rales d'entreprise et aux besoins de fonds de roulement.
BioSig Technologies (NASDAQ: BSGM), das k眉rzlich mit Streamex Exchange Corporation fusionierte, hat ein 枚ffentliches Angebot 眉ber 15 Millionen US-Dollar von Stammaktien abgeschlossen. Das Unternehmen verkaufte 3.852.149 Aktien zu je 3,90 USD, wobei keine vorfinanzierten Warrants in die Struktur aufgenommen wurden.
Das Angebot, gemeinschaftlich von Clear Street und Needham & Company betreut, erfolgte unter einer wirksamen S-3-Registrierung. Die Nettoerl枚se werden haupts盲chlich zum Kauf von Goldbarren gem盲脽 der Anlagepolitik des Unternehmens sowie f眉r allgemeine Unternehmenszwecke und zur Finanzierung des Umlaufverm枚gens verwendet.
- Successfully raised $15 million through public offering
- Strategic offering structure with no dilutive warrants
- Proceeds allocated for gold bullion acquisition and business growth
- Support from technology and mining thought leaders as investors
- Dilution of existing shareholders through new share issuance
- Offering price of $3.90 represents potential discount to market price
Insights
BioSig raises $15M through stock offering at $3.90/share without warrants, strengthening its position in gold tokenization following its Streamex merger.
BioSig Technologies has successfully closed its
The offering's structure reveals several strategic advantages. First, the absence of warrants prevents future dilution that typically occurs when warrant holders convert their securities. This shareholder-friendly approach demonstrates management's confidence in maintaining equity value. Second, the company attracted what they describe as "technology and mining thought leaders" as investors, potentially bringing valuable expertise and industry connections beyond just capital.
The allocation of proceeds gives insight into the company's post-merger direction. Management intends to use the funds primarily to purchase gold bullion in accordance with its investment policy, alongside general corporate purposes and working capital. This directly supports their new business model as a "Nasdaq-listed leader in the gold bullion based real world asset space."
With Clear Street and Needham & Company as joint book-running managers, the offering was conducted through an existing shelf registration statement, indicating the company had planned for potential capital raises. CEO Henry McPhie's statement suggests this funding completes their capital strategy requirements for the current growth phase, allowing management to shift focus toward "accelerated shareholder value creation" through operational execution.
Offering Structured to Accelerate Streamex鈥檚 Operational Build-Out, Strategically Allocated with No Warrants
Los Angeles, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (鈥淏ioSig鈥� or the 鈥淐ompany鈥�), which recently merged with Streamex Exchange Corporation (鈥淪treamex鈥�) (NASDAQ: BSGM), a gold tokenization infrastructure company, today announced the closing of its previously announced underwritten public offering, including a group of technology and mining thought leaders.
The offering consisted of 3,852,149 shares of common stock at a public offering price of
The Company intends to use the net proceeds from the offering to purchase gold bullion in accordance with the Company鈥檚 investment policy, for general corporate purposes and for working capital.
鈥淲e now have been able to marry a short and long-term capital strategy for the company with high-quality shareholders to support this pivotal point in our development,鈥� Henry McPhie, CEO of BioSig and Co-Founder of Streamex. 鈥淲e are building a Nasdaq-listed leader in the gold bullion based real world asset space and we can now focus on accelerated shareholder value creation.鈥�
Clear Street and Needham & Company are acting as joint book-running managers of the offering.
The offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-276298) declared effective by the Securities and Exchange Commission (the 鈥淪EC鈥�) on December 17, 2024. A final prospectus supplement relating to the offering has been filed with the Securities and Exchange Commission, together with an accompanying base prospectus. The securities were offered only by means of a written prospectus forming a part of the effective registration statement. Copies of the final prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained from the SEC鈥檚 website at http://www.sec.gov, from Clear Street, Attention: Syndicate, 4 World Trade Center, 150 Greenwich St, Floor 46, New York, NY 10007, or by email at and Needham & Company, 250 Park Avenue, 10th Floor, New York, NY 10177, Attn: Prospectus Department, or by telephone at (800) 903-3268.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. BioSig will not, and has been advised by the joint book-running managers that they and their affiliates will not, sell any of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Streamex
Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and an institutional grade tokenization platform.聽 Streamex is a wholly owned subsidiary of BioSig Technologies, Inc.
About BioSig Technologies
BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP鈩� Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias.
The PURE EP鈩� Platform enables electrophysiologists to acquire raw signal data in real-time鈥攁bsent of unnecessary noise or interference鈥攖o maximize procedural success and minimize unnecessary inefficiencies. As physician advocates, we believe that the ability to maintain the integrity of intracardiac signals with precision and clarity without driving up procedural costs has never been more pertinent.
Forward-Looking Statements
This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥減lans,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥減rojects,鈥� 鈥減redicts,鈥� 鈥渆stimates,鈥� 鈥渁ims,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥減otential,鈥� or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition and recently announced convertible debenture financing and standby equity purchase agreement will be obtained, and whether we will be able to maintain compliance with Nasdaq鈥檚 listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled 鈥淩isk Factors鈥� in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
Contacts Ele Kauderer [email protected] +1 888-228-0122 Henry McPhie CEO of BioSig, Co-Founder of Streamex [email protected] https://x.com/streamex
FAQ
How much did BioSig Technologies (BSGM) raise in its August 2025 public offering?
What will BioSig Technologies use the proceeds from its 2025 offering for?
Who were the underwriters for BioSig's $15 million offering in 2025?
Were there any warrants included in BioSig's August 2025 public offering?
What is BioSig Technologies' new business focus after the Streamex merger?
